Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

PLX
Protalix BioTherapeutics, Inc. Common Stock
stock NYSEAMERICAN

Market Open
Jul 10, 2025 10:40:47 AM EDT
1.51USD-1.307%(-0.02)88,884
1.50Bid   1.51Ask   0.01Spread
Pre-market
Jul 10, 2025 8:49:30 AM EDT
1.50USD-1.961%(-0.03)350
After-hours
Jul 9, 2025 4:18:30 PM EDT
1.54USD+1.980%(+0.03)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsMore
open chart   
open chart   
Market Cap
120.05M
Headquarters
2 Snunit St Science Park Pob 455, Karmiel, Israel
Industry
Biotechnology
Next Earnings
Aug 18, 2025 (39d)
Last Split
Dec 20, 20191for10reverse
Related
NBIXFOLDPFETEVAXLV
PLX Stats
Avg. Vol. 10 Day
1,893,726
Avg. Vol. 30 Day
1,065,908
Employees
190
Market Cap
120,047,529
Shares Out.
79,607,115
On/Off Exchange
47%/53%
6 Month Beta
0.63
1 Year Beta
0.56
2 Year Beta
0.64
3 Year Beta
0.47
52 Week Low
0.82
52 Week High
3.10
SMA50
1.79
SMA200
1.89
1 Week
-2.08%
1 Month
-4.56%
3 Month
-34.72%
6 Month
-33.57%
1 Year
+34.64%
2 Year
-18.93%
5 Year
-56.79%
Profile
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher's disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase

PLX Stock Summary

Protalix BioTherapeutics, Inc. Common Stock (NYSEAMERICAN:PLX) stock price today is $1.51, and today's volume is 88,884. PLX is down -1.307% today. The 30 day average volume is 1,065,908. PLX market cap is 120.05M with 79,607,115 shares outstanding.



Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC